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Prior use of direct oral anticoagulants has been associated with reduced stroke severity in
patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to investigate
the impact of prothrombin time (PT) and activated partial thromboplastin time (aPTT) on
stroke severity in patients who were receiving dabigatran or rivaroxaban at the time of stroke
onset.
Materials and methods
We enrolled 107 patients with NVAF who developed acute ischemic stroke while on dabiga-
tran or rivaroxaban and presented within 24 hours to nine hospitals between January 2014
and December 2018. The results of PT and aPTT assays were obtained within 24 hours of
stroke onset in all patients. We analyzed PT and aPTT in relation to stroke severity and
ischemic lesion volume using correlation and multivariable regression analyses.
Results
Of the 107 patients included, 46 (43.0%) were on dabigatran and 61 (57.0%) were on rivar-
oxaban. In patients with prior dabigatran use, while aPTT was inversely correlated with
admission National Institutes of Health Stroke Scale (NIHSS) score (r = -0.369, p = 0.012)
and ischemic lesion volume (r = -0.480, p = 0.005), there was no correlation between PT
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and either of these variables. Multivariable analysis confirmed the existence of a significant
independent inverse relationship between aPTT and NIHSS score at admission (B, -0.201;
95% confidence interval [CI], -0.370 to -0.032; p = 0.005) and between aPTT and ischemic
lesion volume (B, -0.076; 95% CI, -0.130 to -0.023; p = 0.007). In patients with prior rivaroxa-
ban use, neither PT nor aPTT was associated with admission NIHSS score or ischemic
lesion volume in the correlation and multivariable analyses.
Conclusions
In patients with NVAF who were receiving dabigatran, prolonged aPTT was associated with
reduced stroke severity.
Introduction
Non-valvular atrial fibrillation (NVAF) is the most common type of cardiac arrhythmia associ-
ated with an increased risk of cardioembolism [1]. Patients with cardioembolic stroke are
known to have more severe neurological deficits and a poorer functional outcome than those
with other types of ischemic stroke [2, 3]. Oral anticoagulants are used for primary and sec-
ondary stroke prevention in patients with NVAF [4–6]. In addition, prior use of oral anticoag-
ulants has been shown to reduce stroke severity and subsequently improve functional outcome
[7, 8].
In patients with NVAF who suffer an ischemic stroke, stroke outcome has been shown to
differ according to the activity of oral anticoagulants [9]. Notably, specific coagulation tests,
including diluted thrombin time and chromogenic anti-Xa assays, have demonstrated a strong
correlation with plasma concentrations of direct oral anticoagulants (DOACs) [10]. However,
the availability of these specialized tests is limited and they require personnel with laboratory
experience, which restricts their implementation in clinical practice. Several experimental
studies have shown that routine coagulation tests such as prothrombin time (PT) and activated
partial thromboplastin time (aPTT) assays could provide qualitative estimates of the anticoag-
ulant activity of dabigatran and rivaroxaban [10]. Therefore, stroke outcomes such as stroke
severity and ischemic lesion volume could differ according to PT and aPTT in stroke patients
on dabigatran or rivaroxaban. However, little is known about this issue, and further research is
thus required.
The aim of this study was to investigate the impact of PT and aPTT on stroke severity in
patients with NVAF who were receiving dabigatran or rivaroxaban at the time of stroke onset.
Materials and methods
Study population
We retrospectively reviewed the medical records of consecutive patients with NVAF who suf-
fered an acute ischemic stroke while taking a DOAC and presented within 24 hours of symp-
tom onset to the neurology department of nine hospitals between January 2014 and December
2018. After obtaining data on the type, dose, and time of last DOAC intake, we included 107
patients who were taking dabigatran or rivaroxaban. We excluded patients taking apixaban or
edoxaban from this analysis because apixaban has been reported to be less sensitive to PT and
aPTT assays than other DOACs [11–13] and edoxaban entered the Korean market in 2016,
which was in the middle of our intended study period. In addition, patients were also excluded
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if they had taken their last DOAC dose more than 48 hours before the index stroke or if the
time of last DOAC intake was unknown.
All patients underwent brain imaging, neurological examination, and routine coagulation
tests, including PT and aPTT assays. The diagnosis of acute ischemic stroke was made by
stroke neurologists and confirmed based on computed tomography or magnetic resonance
imaging. The presence of AF was determined by electrocardiography. PT and aPTT assays
were performed within 24 hours of symptom onset in all patients. These assays were carried
out in the laboratory of each hospital according to the manufacturer’s instructions. In this
study, PT was expressed in seconds (s) because its conversion to international normalized
ratio (INR) does not correct for the variability resulting from the use of different thromboplas-
tins [13, 14]. This study was approved by the institutional review board of each participating
hospital and each board waived the need for patient consent (Pusan National University Hos-
pital H-2004-035-090, Pusan National University Yangsan Hospital 05-2020-165, Severance
Hospital 4-2019-1273, Gangnam Severance Hospital 3-2018-0046, Kyung Hee University Hos-
pital KHNMC-2019-10-008, Changwon Fatima Hospital CHF-2019-12, Ulsan University Hos-
pital 2020-08-006, Sanggye Paik Hospital 2019-04-018-001, and Busan Paik Hospital 2019-03-
0024).
Clinical data
We collected data on baseline characteristics and vascular risk factors such as hypertension,
diabetes mellitus, dyslipidemia, and cigarette smoking. Patients were considered smokers if
they had smoked within the 3-month period before admission. Data on each patient’s history
of ischemic heart disease, ischemic stroke, peripheral arterial occlusive disease, and congestive
heart failure were also obtained. Based on these data, we calculated the CHA2DS2-VASc score
before the index stroke. Stroke subtype was determined according to the Trial of Org 10172 in
Acute Stroke Treatment (TOAST) criteria [15].
Preadmission functional status was determined using the modified Rankin Scale (mRS),
and initial stroke severity was assessed according to the National Institutes of Health Stroke
Scale (NIHSS) score at admission.
We obtained the results of blood tests performed at admission, including lipid and creati-
nine levels. Serum creatinine clearance (CrCl) was calculated using the Cockcroft-Gault
equation.
Patients were categorized into two groups according to the dose of DOAC and level of
CrCl. The standard-dosed group included patients receiving dabigatran 150 mg twice daily
(110 mg twice daily in patients with CrCl 30−49 mL/min) or rivaroxaban 20 mg once daily (15
mg once daily in patients with CrCl 15−49 mL/min). Therefore, patients who were receiving a
DOAC dose lower than the abovementioned recommended dose were included in the under-
dosed group. Data on the concomitant use of antiplatelet agents or statins with dabigatran or
rivaroxaban were also obtained.
Radiologic data
Ischemic lesion volume was measured based on initial diffusion-weighted imaging (DWI)
using MIPAV software (version 8.0.2., http://mipav.cit.nih.gov). For this analysis, we excluded
patients who underwent DWI after acute reperfusion therapy (n = 21), those whose DWI were
unavailable (n = 5), those without ischemic lesions (n = 3), and those with artifacts (n = 3) or
hemorrhagic transformation (n = 3) on DWI. Finally, 72 (67.3%) patients were included in the
volumetric analysis. Two observers (H.-J.C. and Y.J.K.) manually outlined the hyperintense
lesions on the initial DWI, and the acute ischemic lesion volume was automatically calculated
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by multiplying the lesion area in each section by the slice thickness. Acute ischemic lesion vol-
ume was measured independently by the two observers, and the mean value was then
calculated.
Statistical analysis
Categorical variables were expressed as frequency (percentage). Continuous variables were
presented as median (interquartile range [IQR]) and were compared using the Mann-Whitney
U test. We analyzed the correlation between PT/aPTT and admission NIHSS score and
between PT/aPTT and ischemic lesion volume using Spearman’s correlation test. To minimize
bias owing to the NIHSS scores being restrained by lower and upper bounds, we conducted
univariable and multivariable Tobit regression analyses to determine the factors independently
associated with admission NIHSS score. Multivariable linear regression analysis was per-
formed to identify the independent variables associated with ischemic lesion volume. Natural
log transformation of the ischemic lesion volume was performed to reduce skewness and
obtain a distribution more appropriate for correlation and multivariable linear regression
analyses. The results were presented as B (95% confidence interval [CI]). P-values <0.05 were
considered statistically significant. All statistical analyses were performed with SPSS for Win-




The median age of the 107 patients enrolled in this study was 75.0 years (IQR, 68.0−81.0), and
53 (49.5%) patients were male. The median time from symptom onset to hospital arrival and
time from symptom onset to the acquisition of PT and aPTT results were 3.6 h (IQR, 1.2
−11.2) and 5.4 h (IQR, 2.3−12.7), respectively. Dabigatran and rivaroxaban were prescribed in
39 (36.4%) patients for primary stroke prevention and in 68 (63.6%) patients for secondary
stroke prevention. The median NIHSS score on admission was 7.0 (IQR, 3.0−15.0) and the
median preadmission CHA2DS2-VASc score was 5.0 (IQR, 3.0−6.0). The median PT and
aPTT were 13.4 s (IQR, 11.7−15.0) and 34.0 s (IQR, 29.9−40.6), respectively.
Of the 107 patients, 46 (43.0%) received dabigatran and 61 (57.0%) received rivaroxaban.
Table 1 provides the baseline characteristics of patients in the dabigatran and rivaroxaban
groups. The PT of the rivaroxaban group was significantly longer than that of the dabigatran
group [14.2 s (IQR, 11.8−17.1) vs. 12.9 s (IQR, 11.6−14.2), p = 0.010]. On the contrary, the
dabigatran group had a significantly prolonged aPTT compared with the rivaroxaban group
[37.3 s (IQR, 29.2−46.7) vs. 33.3 s (IQR, 30.0−38.8), p = 0.034].
Dabigatran group
The median NIHSS score was 6.5 (IQR, 2.0−14.3). The median ischemic lesion volume, which
was measured in 32 (69.6%) patients, was 2.8 cm3 (IQR, 0.9−12.1). Spearman’s correlation
analysis showed that there was a significant inverse correlation between aPTT and admission
NIHSS score (r = -0.369, p = 0.012) and between aPTT and ischemic lesion volume (r = -0.480,
p = 0.005; Fig 1 and S1 Table). However, PT did not correlate with admission NIHSS score or
ischemic lesion volume (S1 Table). In the univariable Tobit regression analysis, hypertension
(B, 4.924; 95% CI, 0.369 to 9.479; p = 0.034), previous ischemic heart disease (B, 5.962; 95% CI,
1.136 to 10.788; p = 0.015), and a shorter aPTT (B, -0.251; 95% CI, -0.425 to -0.077; p = 0.005)
were associated with a higher NIHSS score at presentation. After adjusting for significant
PLOS ONE Effects of dabigatran and rivaroxaban on stroke severity
PLOS ONE | https://doi.org/10.1371/journal.pone.0240483 October 12, 2020 4 / 10
Table 1. Baseline characteristics of patients receiving dabigatran or rivaroxaban.
Dabigatran (N = 46) Rivaroxaban (N = 61)
Male 26 (56.5) 27 (44.3)
Age, years 74.5 (64.8–79.3) 75.0 (68.0–81.5)
Onset to arrival, hours 3.6 (0.7–12.5) 3.7 (1.3–11.1)
Onset to PT/aPTT results, hours 5.5 (1.9–13.7) 5.2 (2.6–11.9)
Preadmission mRS score 0.0 (0.0–1.0) 0.0 (0.0–2.0)
Stroke subtype
Cardioembolic 41 (89.1) 50 (82.0)
Undetermined 5 (10.9) 11 (18.0)
Risk factors
Hypertension 33 (71.7) 47 (77.0)
Diabetes 16 (34.8) 15 (24.6)
Dyslipidemia 14 (30.4) 17 (27.9)
Smoking 9 (19.6) 2 (3.3)
Previous ischemic heart disease 10 (21.7) 16 (26.2)
Previous ischemic stroke 30 (65.2) 38 (62.3)
CHA2DS2-VASc score 4.5 (3.0–6.0) 5.0 (4.0–6.0)
Under-dosed DOAC 19 (41.3) 16 (26.2)
Reperfusion therapy 7 (15.2) 14 (23.0)
Concomitant medication
Antiplatelet agent 2 (4.3) 11 (18.0)
Statin 27 (58.7) 29 (47.5)
Laboratory findings
PT, s 12.9 (11.6–14.2) 14.2 (11.8–17.1)
aPTT, s 37.3 (29.2–46.7) 33.3 (30.0–38.8)
Total cholesterol, mmol/L 3.7 (3.2–4.4) 3.7 (3.1–4.5)
LDL cholesterol, mmol/L 2.2 (1.7–2.7) 2.1 (1.5–2.9)
Creatinine clearance, mL/min 67.9 (50.8–82.9) 61.2 (41.4–75.8)
Values are number (column %) or median (interquartile range).
PT, prothrombin time; aPTT, activated partial thromboplastin time; mRS, modified Rankin Scale; DOAC, direct oral anticoagulant; LDL, low-density lipoprotein.
https://doi.org/10.1371/journal.pone.0240483.t001
Fig 1. Correlations of aPTT in patients with prior dabigatran use. Scatter plots show the inverse associations
between aPTT and admission NIHSS score (A) and between aPTT and acute ischemic lesion volume (B). aPTT,
activated partial thromboplastin time; NIHSS, National Institutes of Health Stroke Scale.
https://doi.org/10.1371/journal.pone.0240483.g001
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confounders, the multivariable Tobit regression analysis showed a statistically significant
inverse association between aPTT and admission NIHSS score (B, -0.201; 95% CI, -0.370 to
-0.032; p = 0.020; Table 2). A statistically significant inverse association between aPTT and
ischemic lesion volume was also identified in the multivariable linear regression analysis (B,
-0.076; 95% CI, -0.130 to -0.023; p = 0.007; Table 3).
Rivaroxaban group
The median NIHSS score was 9.0 (IQR, 3.0−16.0), and the median ischemic lesion volume,
which was measured in 40 (65.6%) patients, was 6.9 cm3 (IQR, 2.4−19.9). In the Spearman’s
correlation analysis, no significant correlations were identified between PT/aPTT and admis-
sion NIHSS score or ischemic lesion volume (S1 Table). The multivariable Tobit regression
analysis showed that concomitant use of antiplatelet agents was significantly associated with a
higher admission NIHSS score (B, 7.050; 95% CI, 1.711 to 12.389; p = 0.010; Table 2). Con-
comitant use of antiplatelet agents was also significantly associated with a greater ischemic
lesion volume in the multivariable linear regression analysis (B, 1.540; 95% CI, 0.125 to 2.956;
p = 0.034; Table 3). However, neither PT nor aPTT was associated with admission NIHSS
score or ischemic lesion volume (Tables 2 and 3).
Discussion
This study demonstrated an independent inverse relationship between aPTT on admission
and stroke severity in patients with prior dabigatran use. However, PT was not associated with
a reduction in stroke severity in patients on dabigatran or rivaroxaban.
In this study, the anticoagulant activity of dabigatran and rivaroxaban was assessed using
PT and aPTT assays. Several experimental studies have focused on the application of coagula-
tion tests for measuring DOAC activity [10]. Specific coagulation tests such as diluted throm-
bin time or ecarin-based assays could be used to accurately determine dabigatran activity as
Table 2. Multivariable Tobit regression analysis of the independent factors associated with stroke severity.
Dabigatran Rivaroxaban
B (95% CI) P-value B (95% CI) P-value
Hypertension 3.509 (-0.695 to 7.713) 0.102 ― ―
Previous ischemic heart disease 3.848 (-0.782 to 8.478) 0.103 ― ―
Antiplatelet agent ― ― 7.050 (1.711 to 12.389) 0.010
PT ― ― ― ―
aPTT -0.201 (-0.370 to -0.032) 0.020 ― ―
B, standard coefficient; CI, confidence interval; PT, prothrombin time; aPTT, activated partial thromboplastin time.
https://doi.org/10.1371/journal.pone.0240483.t002
Table 3. Multivariable linear regression analysis of the independent factors associated with ischemic lesion volume.
Dabigatran Rivaroxaban
B (95% CI) P-value B (95% CI) P-value
Diabetes ― ― 0.981 (-0.223 to 2.186) 0.107
Antiplatelet agent ― ― 1.540 (0.125 to 2.956) 0.034
PT ― ― ― ―
aPTT -0.076 (-0.130 to -0.023) 0.007 ― ―
B, standard coefficient; CI, confidence interval; PT, prothrombin time; aPTT, activated partial thromboplastin time.
https://doi.org/10.1371/journal.pone.0240483.t003
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they strongly reflect the plasma concentration of this DOAC [16]. With respect to rivaroxaban,
the chromogenic anti-Xa assay best reflects the plasma concentration of this DOAC [17].
However, these specific tests are not widely available in routine practice because they are typi-
cally performed in specialized coagulation laboratories and cannot be performed outside of
daytime working hours. Indeed, in a previous study, less than half of all patients who presented
with acute ischemic stroke while on DOAC therapy underwent specific coagulation tests in
routine clinical practice [11]. Therefore, it would be helpful to understand the impact of
DOACs on the results of routine coagulation tests utilized in clinical practice such as PT and
aPTT assays.
Previous studies have shown a significant association between stroke outcomes and antico-
agulant activity assessed using PT-INR in NVAF patients receiving warfarin [7, 8, 18]. In our
study, a longer aPTT was significantly associated with reduced stroke severity and a smaller
infarction volume in patients receiving dabigatran. aPTT has been experimentally reported to
correlate with plasma dabigatran concentration in a curvilinear manner [19–22]. We speculate
that a longer aPTT in patients on dabigatran may result in a smaller embolus size, enhanced
embolus resolution, and reduced thrombus propagation, which may lead to decreased stroke
severity [23, 24]. However, PT was not associated with stroke severity in patients on dabiga-
tran, which correlates with previous experimental evidence showing that PT is less sensitive to
dabigatran than aPTT [16, 20]. Previously, a prolonged aPTT (more than two times the upper
limit of normal) was shown to be a predictor for bleeding events in patients on dabigatran
[25]. However, there is a lack of data on the association between aPTT and ischemic stroke
outcomes [26]. Our results may provide clinical evidence that the ability of dabigatran to
reduce stroke severity is dependent on aPTT.
Previous experimental studies have revealed a linear correlation between PT and plasma
rivaroxaban concentration [12, 17, 21]. However, aPTT may not be suitable for the evaluation
of rivaroxaban activity because of its unresponsiveness and poor sensitivity to this DOAC [27].
Our study showed that neither PT nor aPTT was associated with a significant reduction in
stroke severity in patients with prior rivaroxaban use. This discrepancy may be due to the fact
that the thromboplastin reagents used in the PT assay were not identical among the participat-
ing institutes. In a previous study, different PT reagents showed highly variable sensitivities to
rivaroxaban at the same plasma concentration [17]. Therefore, in our study, the ability of PT
to accurately reflect the anticoagulant activity of rivaroxaban may have differed according to
the reagents used.
There are limitations of this study that should be considered. First, this was a retrospective
study with a small sample size. Therefore, unrecognized biases might have affected the validity
of the results. The small number of patients included might be due to the low incidence of
ischemic stroke in patients taking DOACs. Further larger prospective studies are needed to
confirm the findings of our study. Second, we did not assess short-term or long-term out-
comes due to the retrospective nature of this study. However, stroke severity on admission is
an important predictor of functional outcomes in patients with ischemic stroke [28]. Although
several studies have reported that anticoagulation therapy prior to ischemic stroke was associ-
ated with improved functional outcomes in patients with NVAF, this benefit was attenuated or
no longer significant after adjusting for initial stroke severity [23, 29, 30]. Moreover, the long-
term and even short-term outcomes of patients with ischemic stroke could be influenced by
multiple factors after stroke onset. In this study, we sought to purely investigate the impact of
the anticoagulant activity of two DOACs on stroke severity. Third, although several factors
including inflammation and immune responses are known to be associated with stroke sever-
ity, these factors were not fully taken into consideration and adjusted for in this study [31, 32].
Finally, the interval between symptom onset and hospital arrival could have led to an
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underestimation of PT or aPTT at the time of stroke onset. However, we only included
patients who presented within 24 hours of symptom onset. In particular, 33 patients (71.7%)
in the dabigatran group and 47 (77.0%) in the rivaroxaban group presented to the hospital
within 12 hours, which might have somewhat reduced the potential bias caused by the time lag
between symptom onset and acquisition of the blood sample.
Conclusions
Our study suggests that the ability of dabigatran to reduce stroke severity may be influenced by
its anticoagulant activity in patients with NVAF. In addition, the aPTT assay can be easily used
in clinical practice to estimate the anticoagulant activity of dabigatran. The accumulation of
more clinical data is needed to support the findings of our study.
Supporting information
S1 Table. Correlations between PT/aPTT and stroke severity or ischemic lesion volume in
patients on dabigatran or rivaroxaban.
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